Clinical Trials Browser

Phase 3 × Has announcements × olaparib × Clear all

NCT02032823 2026-05-06

OlympiA

Phase 3 Active not recruiting

1,837 enrolled 20 charts 1 FDA

Breast Neoplasms

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

302 enrolled 26 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Phase 3 Active not recruiting

895 enrolled 19 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 1 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3 Active not recruiting

327 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT03737643 2025-01-29

DUO-O

Phase 3 Active not recruiting

1,407 enrolled 1 FDA

Ovarian Neoplasms

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 3 Completed

387 enrolled 16 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer

NCT02184195 2023-09-13

POLO

Phase 3 Completed

154 enrolled 20 charts 1 FDA

Gastrointestinal

Pancreatic Neoplasms